Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMILE trial: L-glutamine in sickle cell disease
2022-001585-36Phase 2
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of glutamine in sickle cell disease (SCD) and Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia), sponsored by Amsterdam University Medical Center. Primary endpoint: Primary endpoint: relative decrease in Point of Sickling at 12 weeks.
02
Drugs
glutamine
03
Conditions
sickle cell disease (SCD)Hemoglobin S-beta-zero thalassemia (HbSβ⁰-thalassemia)
Beyond the preview
Go deeper on 2022-001585-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001585-36.